HMR 59

Drug Profile

HMR 59

Alternative Names: AAVCAGsCD59; HMR59

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tufts University
  • Developer Hemera Biosciences; Tufts University
  • Class Eye disorder therapies; Gene therapies; Recombinant proteins
  • Mechanism of Action Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dry age-related macular degeneration
  • No development reported Wet age-related macular degeneration

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Intravitreous, Injection)
  • 29 Mar 2017 Phase-I clinical trials in Dry age-related macular degeneration (In the elderly) in USA (Parenteral) (NCT03144999)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top